Atorvastatin for HAART Suboptimal Responders

• Status: Completed
• Trial end date: 2014-03-01

Summary

We hypothesise that atorvastatin changes immune activation among HAART-treated adults with suboptimal cluster cell differentiation 4 (CD4) recovery by 25%

• Phase: Phase 3

Details

• Lead Sponsor: Makerere University
• Collaborator: Vaccine and Gene Therapy Institute, Florida
• Treatments: Atorvastatin; Atorvastatin Calcium